<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
Shares of Bluebird Bio Inc. BLUE, -3.25% were down 21.6% in premarket trading on Monday after the company announced several setbacks to its business as part of its second-quarter earnings announcement. Bluebird plans to wind down its gene therapy operations in Europe, citing “European payers,” which are primarily governments there.
...read full article on Market Watch
